1. Investors

KPIs

We use a number of key performance indicators (KPIs) to assess progress against our strategic objectives

As part of our commitment to enhanced narrative reporting, we measure our performance against a number of financial and non-financial KPIs that are aligned to our strategic priorities. These KPIs are not specific targets; they are metrics that are reported on each year to show progression of the business and reflect the nature of the asset class.

Targeting a portfolio of 20-25 companies, creating 3 new companies a year, with a goal of delivering 3-5 companies to late-stage development over a rolling 10-year basis

Rationale

By creating three new companies per annum we aim to expand the portfolio to 20-25 companies, diversified across clinical stage and therapeutic area.

 

Progress in FY2022/3

  • Portfolio of 13 companies diversified across therapeutic area and development stage
  • Four new companies added to the portfolio
  • £177.2 million of capital deployed during the year, with £83.0 million into late clinical investments
  • Industry leaders Brian Gladsden and David Fellows appointed as CEOs of new portfolio companies Mosaic and Beacon
  • An average number of 3 portfolio companies have been added to the portfolio over the last three years

Access to capital, aim to maintain 3 years of financing runway

Rationale

A deep pool of capital underpins our strategy, enabling us to take a long-term view and support our portfolio companies as they scale, remaining a significant shareholder through to late-stage development.

Progress in FY2022/3

  • £177.2m deployed in the year
  • £650.1m capital pool at 31 March 2023
  • Sale of Neogene to AstraZeneca for up to $320.0 million, with total proceeds to Syncona of up to £21.9 million, including £15.3 million in upfront proceeds1
  • £394.3 million raised across the portfolio, with £176.9 million committed by Syncona
  • 3.7 years of available capital to fund new and existing portfolio companies2

NAV growth

Rationale

We seek to deliver strong risk-adjusted returns for shareholders over the long term, recognising that our NAV can be volatile year on year. We have a long-term target of 15% IRR on NAV and a key metric of five-year compound annual NAV growth at year end.

Progress in FY2022/3

  • Net assets of £1.3 billion
  • (4.1)% NAV return per share in the year
  • (14.3)% return from the life science portfolio in the year with performance impacted by a decline in share prices of listed holdings and the write down of SwanBio

Progress in de-risking pre-clinical and early-stage clinical companies

Rationale

A measurement of progress of our portfolio companies through the clinical pathway.

Progress in FY2022/3

  • Seven portfolio companies at clinical stage
  • Five clinical trials commenced in the year
  • 16 data read-outs across the portfolio

People in the Syncona team

Rationale

The Syncona team is differentiated by its people and the quality of the team’s expertise is critical to the success of the Company. We are also focused on ensuring that we create an inclusive and supportive environment for our people to thrive whilst delivering our strategy.

Progress in FY2022/3

  • Launch of first Employee Engagement Survey
  • Developed first diversity and inclusion framework
  • Updated family friendly policy framework
  • Became a supporter of Level 20, a not-forprofit organisation dedicated to improving gender diversity in European private equity, post-period end
  • Key changes to the structure of the Syncona investment team with Ed Hodgkin promoted to Managing Partner and Elisa Petris and Magdalena Jonikas becoming Lead Partners. Roel Bulthuis joined post-period end as Managing Partner and Head of Investments

Portfolio progress to patient impact

Rationale

A measurement of our progress in delivering transformational treatments to patients.

Progress in FY2022/3

  • Autolus’ obe-cel reached its primary endpoint in its pivotal FELIX trial, in advance of filing a BLA with the US FDA in 2023
  • Addition of late-stage clinical asset to the portfolio in Beacon’s lead programme in XLRP, with Phase II data expected in H2 CY2023
  • 250+ patients in clinical trials

1. FX rate taken at receipt of funds.
2. Capital pool divided by mid-point of capital deployment guidance.
3. To date.

Syncona legal disclaimer

Please read the below disclaimer carefully. You will be asked to accept these terms and conditions before proceeding.

The information on this website is directed only at persons who are shareholders in Syncona Limited (the “Company”) and is provided for their exclusive use and benefit.

Users of this website are responsible for observing all applicable laws and regulations in their relevant jurisdictions before proceeding to access the information contained herein. By proceeding to access the information, users are deemed to be representing and warranting that the applicable laws and regulations of their relevant jurisdiction allow them to do so. No information, materials or opinions contained on this website (“Materials”) constitute or would be deemed to constitute a recommendation or invitation in any jurisdiction to invest or otherwise deal in the shares of the Company (the “Shares”).

The website that you are seeking to access does not constitute an offer to buy or sell the securities mentioned in the website in any jurisdiction or jurisdictions in which such offers or sales are unlawful prior to registration or qualification under the securities laws of any such jurisdiction. In particular, the securities mentioned in the website have not been and will not be registered under the United States Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold in the United States absent registration or exemption from registration under the Securities Act and other securities laws. There will be no public offer of these securities in the United States. Offers and sales of these securities, and distribution of the related information, may also be subject to restrictions in other jurisdictions.

The website that you are seeking to access is not directed at and may not be viewed by or distributed to persons:

  • in the United States or who are U.S persons (as defined in Rule 902 under the Securities Act);

or

  • located in a jurisdiction where it is not lawful to access the materials.

The Materials are provided on an “as is” and “as available basis” and do not purport to be full or complete. The Company and its affiliates believe that the source of the Materials is reliable however they cannot and do not guarantee, either expressly or implicitly, and accept no liability for, the accuracy, validity, timeliness, merchantability or completeness of any information or data (whether prepared by the Company, its affiliates or by any third party) for any particular purpose or use or that the information or data will be free from error. The Company and its affiliates do not undertake any responsibility for any reliance which is placed by any person on any statements or opinions which are expressed herein. Neither the Company, nor any of its affiliates, directors, officers or employees will be liable or have any responsibility of any kind for any loss or damage that any person may incur resulting from the use of this information.Nothing contained in this website constitutes financial, investment, legal, tax or other advice and is not to be relied on in making an investment or other decision. You should obtain relevant and specific professional advice before making any investment decision.

The Materials on this website are provided for your personal use and informational purposes only and are subject to change without notice. The Company has the right to suspend or withdraw the provision of all or any of the website of the Materials without prior notice at any time.

The value of investments mentioned in this site, and the income from them may go down as well as up and investors may not get back the amount invested. Information on past performance, where given, is not a guide to future performance. Changes in rates of exchange between currencies may cause the value of investments to decrease or increase.
The Company is a registered closed-ended collective investment scheme registered pursuant to the Protection of Investors (Bailiwick of Guernsey) Law, 1987, as amended (the ‘‘POI Law’’) and the Registered Collective Investment Scheme Rules 2008 (the ‘‘CIS Rules’’) issued by the Guernsey Financial Services Commission (the ‘‘GFSC’’). Neither the GFSC nor the States of Guernsey Policy Council take any responsibility for the financial soundness of the Company or for the correctness of any of the statements made or opinions expressed with regard to it.

Copyright

Copyright of all images and text in this website is owned by or licensed to the Company or one of its affiliates unless otherwise noted. You may imprint, copy, download or temporarily store extracts from this website for your personal information and use. Any other use is prohibited unless you first request and obtain the prior written consent of the Company. You may not alter or otherwise make any changes to any material that you print or download from this website, including, without limitation, removing any identifying marks or legends from such material. In particular, you may not copy or use any part of this website on any other website, or link any other website to this website, without the prior written permission of the Company. You may not use the website for any purpose which is unlawful, abusive, libellous, obscene or threatening.

No warranty

The Materials contained in this website are provided without any warranty of any kind, either expressed or implied, to the fullest extent permissible pursuant to applicable law. Neither the Company nor its affiliates assume any responsibility for the uninterrupted availability of this website or warrant that it will be error-free, that defects will be corrected, or that this website or the servers that make it available will be free of viruses or other harmful components.

Liability waiver

You agree that under no circumstances, including, but not limited to, negligence, shall the Company or any of its affiliates be liable for any special or consequential damages that result from the access or use of, or the inability to access or use, the Materials on this website. This does not exclude or restrict any duty or liability that the Company has to its customers under the regulatory system in the United Kingdom or Guernsey.

Privacy policy

This policy sets out what the Company and its affiliates do with any personal information collected from this website.

Any personal information collected from this website will be processed in accordance with relevant data protection laws.

You may use the public areas of this website without providing the Company or its affiliates with any personal information and the Company and its affiliates do not monitor or collect any personal information through your access to the public areas of this website. The Company and its affiliates do not use cookies to collect information but may gather other anonymous information to assist in improving the services.

If you chose to provide the Company and its affiliates with personal information, this information will only be used for the purposes of the service that you have requested. The Company and its affiliates will not sell or transfer any personal information to third parties without your permission, other than as required by law.

The Company and its affiliates are not responsible for the content or privacy policies of websites to which this website may link.

The Company and its affiliates are committed to protecting your personal information but in the event that the system is infiltrated by unauthorised third parties the Company and its affiliates will not be liable for any resulting misuse of personal information.

Linked sites

The Company has not reviewed any website linked to this website and is not responsible for the contents of off-site pages or any other websites linked or linking to this website. If you follow any links from this website you do so at your own risk.

Links to this website may not be established without the prior written consent of the Company.

Governing law

The terms and conditions of this legal notice shall be governed by and construed in accordance with the laws of Guernsey. Users of this website agree that any dispute or action arising out of or relating to these terms or any user’s use of this website shall be commenced only in the courts located in Guernsey, and users of this website hereby consent and submit to the exclusive jurisdiction of such courts for the purposes of any such dispute or action.

By accessing Materials on this website you agree to be bound by the foregoing limitations.

I accept I decline

Search